Hello everyone, has anyone tried to modify the amount of tranposome during tagmantation using Nextera? We have already modified the protocol with good results concerning tagmentation time, but we are now considering of decreasing TD and I am worried if this would work....Does anyone know if the Rd1 and Rd2 seq primers are in the TD tube or in the TDE tube (which we do not plan to decrease)?
-
-
I do not know what your aim is to modify the Illumina protocol. TD is 2x tagmentation buffer and if you are planning to modify its amount you will need to proportionally modify your reaction volume. TDE tube contains transposon complex which inserts 19 bp transposase recognition sequences appended with 14-15 nt overhangs to DNA in tagmentation reaction that are used during PCR to add sequencing and flow cell binding motives and index sequences. R1 and R2 sequencing primers come with sequencing kit (MiSeq) or as separate kit which are added to SBS reagents in HiSeq systems. -
I am sorry I meant decreasing TDE!!!!!!!!!!!!!!!!Comment
-
Decreasing TDE without any other modification will results in larger fragments. If you reduce TDE only , then you will not have enough buffer to use it in other reactions. So, if you are aiming for larger fragments it would make more sense to reduce reaction volume (TD, TDE and input DNA) and keep the input DNA amount the same.Comment
-
yes I am aiming for larger fragments! thanks for the info!Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...Yesterday, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment